A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Status:
Recruiting
Trial end date:
2026-10-16
Target enrollment:
Participant gender:
Summary
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) study evaluating the Safety,
Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in patients with relapsed
advanced malignancies (BHARAT-1).